ANVISA Priority Review Program: Clinical Trial Approval Timelines for Strategic Diseases

Key Takeaways

• 120-day approval: Priority review cuts clinical trial registration timelines by 67% compared to standard 365-day processes for diseases of public health relevance.
• Four strategic categories: Neglected diseases, emerging/re-emerging diseases, rare diseases (≤65 per 100,000), and serious pediatric conditions qualify for prioritization.
• Dual regulatory framework: RDC 204/2017 governs general prioritization criteria; RDC 205/2017 establishes special procedures for rare diseases.
• 2024 law update: Law 14.874/2024 introduced fixed 90-day standard timelines and 60-day priority pathways, further streamlining regulatory approval processes in Brazil.

What Is ANVISA's Priority Review Program?

Brazil's National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA) operates the Priority Review Program to accelerate access to medicines addressing unmet medical needs. RDC 204/2017, published December 27, 2017, defines the program's scope and procedures.

The program prioritizes requests for marketing authorization, post-marketing authorization changes, and clinical trial approvals. Article 1 of RDC 204/2017 states the goal: ensuring or increasing access to pharmaceutical assistance based on public relevance.

ANVISA assigns applications to "priority" or "ordinary" categories based on clinical, economic, and social benefits. This classification determines review timelines and resource allocation.

How Do Standard and Priority Timelines Compare?

The timeline differential between standard and priority review is substantial. Regulatory analysis documented in ANVISA's 2024 regulatory consultation clarifies the specific deadlines:

Table 1: ANVISA Clinical Trial and Registration Timelines

Process Type	Priority Category	Ordinary Category
Clinical Trial Approval	30–45 days (rare diseases: 30 days)	90 business days (Law 14.874/2024)
Drug Registration	120 days	365 days
Post-Registration Changes	60 days	180 days
Good Manufacturing Practice (CBPF)	120 days	365 days

For rare diseases specifically, RDC 205/2017 establishes expedited 30-day clinical trial approval timelines. This reflects Brazil's commitment to accelerating access for small patient populations.

Which Diseases Qualify for Priority Review?

ANVISA defines four strategic disease categories eligible for priority review:

Neglected diseases: Conditions not economically attractive for drug development, primarily affecting populations in developing countries. These include parasitic and bacterial infections endemic to tropical regions.

Emerging and re-emerging diseases: New health conditions, usually infectious, or known conditions that acquire epidemiologic significance in public health. This includes novel pathogens and antimicrobial-resistant variants with epidemic potential.

Rare diseases: Conditions affecting up to 65 in 100,000 people, per Brazil's Policy on Full Attention to People with Rare Diseases. Rare disease treatments receive expedited review under RDC 205/2017.

Serious debilitating conditions: Diseases associated with irreversible morbidity or high death probability unless the disease course is interrupted. Pediatric conditions within this category receive priority consideration.

What Changed Under Law 14.874/2024?

Brazil's Law 14.874/2024, enacted in May 2024 and effective August 26, 2024, fundamentally restructured clinical trial regulation. The legislation introduced three core reforms:

First, ethical approval decentralization. The law eliminated Brazil's centralized ethics committee (CONEP), transferring authority to local institutional ethics committees (CEPs). This removes a bottleneck that previously added months to trial initiation.

Second, fixed regulatory timelines. ANVISA must now complete clinical trial application reviews within 90 business days. If ANVISA does not respond, trials may proceed after CEP approval. Strategic research for Brazil's Unified Health System (SUS) receives 15-day ethics review and 60-day regulatory review.

Third, tacit approval mechanisms. The law establishes that silence from ANVISA after the deadline constitutes approval. This contrasts with pre-2024 procedures where indefinite delays were common.

According to Mattos Filho legal analysis, the 90–120 business day window represents approximately 4.5 to 6 months in calendar time—a significant improvement over previous variable timelines.

How Does ANVISA Compare to FDA and EMA?

ANVISA's priority review framework aligns with international standards while addressing Brazilian public health priorities. The 120-day registration timeline compares favorably to FDA's standard 10-month review and EMA's 210-day active review period.

Key differences exist in scope. ANVISA's program uniquely emphasizes diseases affecting LATAM populations, including neglected tropical diseases rarely addressed in North American or European markets. Malaria, dengue, and Chagas disease receive priority consideration reflecting regional disease burden.

The 2024 law harmonizes Brazilian procedures with ICH E6(R2) Good Clinical Practice guidelines. This alignment facilitates multi-regional trials incorporating Brazilian sites.

What Are the Strategic Implications for Sponsors?

The accelerated pathway creates competitive advantages for pharmaceutical companies. Sponsors developing therapies for neglected diseases or rare conditions can now plan with predictable regulatory timelines.

Brazil's regulatory improvements enhance its attractiveness as a clinical trial destination. Fixed 90-day reviews with tacit approval provisions reduce regulatory uncertainty. For oncology trials, where enrollment windows are narrow, predictable timelines enable better site coordination.

What to watch: ANVISA may expand priority categories based on Consulta Pública 1.294/2024, which proposes revising RDC 204/2017 criteria. The consultation, extended through February 2025, seeks stakeholder input on preventing queue stagnation while maintaining public health focus.

Frequently Asked Questions

Primary Sources

1. Brazilian Health Regulatory Agency (ANVISA). RDC 204/2017: Collegiate Board Resolution Prioritizing Marketing Authorization and Clinical Research Requests. Published December 27, 2017; Federal Official Gazette no. 248 of December 28, 2017.
2. Brazilian Health Regulatory Agency (ANVISA). RDC 205/2017: Special Procedure for Rare Diseases Clinical Trials and Marketing Authorization. Published December 28, 2017; Federal Official Gazette no. 249 of December 29, 2017.
3. Brazil. Law 14.874/2024. Provides for Clinical Research in Brazil. Enacted May 2024; effective August 26, 2024.
4. Brazilian Health Regulatory Agency (ANVISA). RDC 945/2024: Clinical Trial Regulation for Drug Marketing Authorization. Published November 29, 2024; effective December 30, 2024.
5. Brazil Ministry of Finance. Technical Opinion on ANVISA Consultation 1.294/2024. Process SEI 19995.009577/2024-35. December 2024.
6. Mattos Filho Advogados. Anvisa Updates Clinical Trial Regulations. December 6, 2024.